Reduced activation and expression of ERK1/2 MAP kinase in the post‐mortem brain of depressed suicide subjects
Open Access
- 1 May 2001
- journal article
- research article
- Published by Wiley in Journal of Neurochemistry
- Vol. 77 (3) , 916-928
- https://doi.org/10.1046/j.1471-4159.2001.00300.x
Abstract
The extracellular regulated kinases (ERK) 1 and ERK2 are members of mitogen‐activated protein (MAP) kinase family that play an important role in transducing extracellular signals to the nucleus and have been implicated in a broad spectrum of biological responses. To test the hypothesis that MAP kinases may be involved in depression, we examined the activation of p44/42 MAP kinase and expression of ERK1 and ERK2 in the post‐mortem brain tissue obtained from non‐psychiatric control subjects (n = 11) and age‐ and the post‐mortem interval‐matched depressed suicide subjects (n = 11). We observed that p44/42 MAP kinase activity was significantly decreased in the prefrontal cortical areas (Brodmann's areas 8, 9 and 10) and the hippocampus of depressed suicide subjects without any change in the cerebellum. This decrease was associated with a decrease in mRNA and protein levels of ERK1 and ERK2. In addition, the expression of MAP kinase phosphatase (MKP)2, a ‘dual function’ ERK1/2 phosphatase, was increased in the prefrontal cortex and hippocampus. These studies suggest that p44/42 MAP kinases are less activated in the post‐mortem brain of depressed suicide subjects and this may be because of reduced expression of ERK1/2 and increased expression of MKP2. Given the role of MAP kinases in various physiological functions and gene expression, alterations in p44/42 MAP kinase activation and expression of ERK1/2 may contribute significantly to the pathophysiology of depressive disorders.Keywords
This publication has 53 references indexed in Scilit:
- Repeated Administration of Dexamethasone Increases Phosphoinositide‐Specific Phospholipase C Activity and mRNA and Protein Expression of the Phospholipase C β1 Isozyme in Rat BrainJournal of Neurochemistry, 1999
- MAP kinase pathwaysProgress in Biophysics and Molecular Biology, 1999
- Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patientsEuropean Journal Of Cancer, 1999
- Activation of a Mitogen-activated Protein Kinase (ERK2) by the 5-Hydroxytryptamine1A Receptor Is Sensitive Not Only to Inhibitors of Phosphatidylinositol 3-Kinase, but to an Inhibitor of Phosphatidylcholine HydrolysisJournal of Biological Chemistry, 1996
- Opposing Effects of ERK and JNK-p38 MAP Kinases on ApoptosisScience, 1995
- Inactivation of p42 MAP kinase by protein phosphatase 2A and a protein tyrosine phosphatase, but not CL100, in various cell linesCurrent Biology, 1995
- The mitogen activated protein kinase signal transduction pathway: From the cell surface to the nucleusCellular Signalling, 1994
- The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domainCell, 1993
- cPLA2 is phosphorylated and activated by MAP kinaseCell, 1993
- Extracellular signal-regulated kinases in T cells: Characterization of human ERK1 and ERK2 cDNAsBiochemical and Biophysical Research Communications, 1992